Expression Of POT1mRNA And TPP1mRNA In Bladder Urothelial Carcinoma

Objective: To detect the expression of telomeric protein POT1(protection of telomeres1)mRNA and TPP1(POT1-interacting protein1)mRNA in bladder urothelial carcinoma. Analysis of the correlation betweenthe expression of the two telomeric protein mRNAs and the correlationbetween the pathological grade or clinical stage in bladder urothelialcarcinoma.Metheods: The32cases of bladder urothelial carcinoma specimens werecollected from bladder cancer surgery patients；the17cases of adjacenttissues specimens were collected；and the12cases of normal bladder mucosaspecimens were collected. The experiment was divided into three groups：thegroup of bladder urothelial carcinoma, the group of adjacent tissues andnormal bladder mucosa tissue group. Total RNA of all specimens of eachgroup were extracted. The expression of POT1mRNA and TPP1mRNA ineach specimens were detected using real-time quantitative polymerase chainreaction(RT-qPCR).Results： The relative amount of POT1mRNA expression was0.0223±0.0043in bladder urothelial carcinoma, which was lower than that inadjacent tissues, the difference between the groups was statistically significant（P＜0.01）; which was lower than that in normal bladder mucosa tissues, thedifference between the groups was statistically significant （P＜0.01）;Compared the relative expression level of POT1mRNA in adjacent tissueswith that in normal bladder mucosa tissues, the difference between the groups was not statistically significant (P=0.619). The relative amount of TPP1mRNA expression was0.0222±0.0039in bladder urothelial carcinoma, whichwas lower than that in adjacent tissues, the difference between the groups wasstatistically significant（P＜0.01）; which was lower than that in normalbladder mucosa tissues, the difference between the groups was statisticallysignificant（P＜0.01）; Compared the relative expression level of POT1mRNA in adjacent tissues with that in normal bladder mucosa tissues, thedifference between the groups was not statistically significant (P=0.715).Between the relative expression of relative POT1mRNA and TPP1mRNAwere into a linear correlation（P＜0.05）. The difference of the relativeexpression levels of POT1and TPP1mRNAs in bladder urothelial carcinomawith pathological grade was no statistically significant (Kruskal-wallis H test)(POT1：H=5.358，P=0.069；TPP1：H=4.552，P=0.103); the difference of therelative expression levels of POT1and TPP1mRNAs in bladder urothelialcarcinoma with Clinical stage was statistically significant (Kruskal-wallis Htest)(POT1：H=9.109，P=0.011；TPP1：H=9.274，P=0.010), and the relativeexpression levels of POT1mRNA and TPP1mRNA increased with theincrease in clinical stage.(Spearman Correlation Analysis POT1: rs=0.542，P=0.002；TPP1: rs=0.537，P=0.001).Conclusion： The expression level of telomeric protein POT1mRNAand TPP1mRNA in bladder urothelial carcinoma tissues were lower than thatin adjacent tissues and normal mucosal tissues. Between the relativeexpression of relative POT1mRNA and TPP1mRNA were into a linearcorrelation. The expression level of both POT1mRNA and TPP1mRNA inbladder urothelial carcinoma had a rank correlation with clinical stage and increased with increasing clinical stage. The reduction of POT1mRNA andTPP1mRNA in bladder urothelial carcinoma tissues may be associated withthe occurrence of bladder tumors and correlated with the pathological gradeor clinical stage in bladder urothelial carcinoma.